1. Elias A, Ryan L, Aisner J, Antman KH: Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. Semin Oncol 1990, 17(Suppl 4):41–49.
2. Heinemann V, Xu Y, Chubb S, et al.: Inhibition of ribo-nucleotide reduction in CCRF-CEM cells by 2',2'-diflu-orodeoxycytidine. Mol Pharmacol 1990, 38:567–572.
3. Huang P, Chubb S, Hertel L, et al.: Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991, 51:6110–6117.
4. Svancarova L, Blay J, Judson I, et al.: Gemcitabine in advanced adult soft tissue sarcomas: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002, 38:556–559. A cooperative group evaluation of gemcitabine in STS.
5. Patel SR, Gandhi V, Jenkins J, et al.: Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001, 19:3483–3489. A phase II trial with the highest reported response rate to gemcitabine.